Gut Peptide Stack: BPC-157 and KPV Capsules, Tri-Blend and KLOW

What is the gut peptide stack?

The gut peptide stack is BPC-157 and KPV used together, most often as one capsule holding 500 mcg of each, for reflux, bloating, IBS or inflammatory bowel disease. It is also sold in premixed vials called Tri-Blend, Wolverine Plus and KLOW. No study has tested the pair, in people or animals. [1], [6]

Both are lab-made peptides studied mainly in animals and cells, and neither is approved as a medicine. BPC-157 is promoted as repairing the gut lining and KPV as calming inflammation. [7], [8]

In community education groups, BPC-157 with KPV is the default suggestion for gut problems. Each part has its own full guide, linked above.

What's in it, and what else is it called?

The core is BPC-157 and KPV. The injectable blends add TB-500 (Tri-Blend and Wolverine Plus) or TB-500 and GHK-Cu (KLOW), which are covered in the healing and recovery stack. Capsules often add other ingredients, such as larazotide (an investigational gut-barrier peptide, not approved), GHK-Cu, TB-500 or zinc carnosine. [23], [24], [25]

A name does not fix what is inside. "Tri-Blend" usually means BPC-157, TB-500 and KPV, but one clinic menu describes its GLOW blend, which has no KPV, as a "tri-blend", and one catalog sells three different formulas as "Wolverine". [3], [17], [19] Even "KPV" on a label is not always KPV: one telehealth catalog sells capsules of N-acetyl BPC-157 and "N-acetyl KPV amidate", modified molecules that differ from the peptides in most studies, with little or no research of their own (see the KPV guide's section on forms and routes). [25] Only the label's amount of each ingredient tells you what a dose contains.

What is in each blend in this stack?

BPC-157 and KPV come premixed in three ways, listed from most to least common: two-part capsules or vials; KLOW, which adds TB-500 and GHK-Cu; and the Tri-Blend or Wolverine Plus vial, which adds TB-500. No blend has been tested in people.

Amounts below are what sellers print on labels, not doses and not proof of contents.

BPC-157 and KPV capsules and two-part vials

The main form for gut use. Capsules usually list 500 mcg of each; a 5 mg + 5 mg injectable vial is rare.

• Where sellers disagree: on extra ingredients and on the molecule form, each one another unknown.
• Stated amounts: one label says one capsule a day on an empty stomach; other schedules are in the protocols. [11]
• Supplement status: these capsules are often sold like supplements, but a US Department of Defense supplement-safety page states that BPC-157 "is not a dietary ingredient", and we found no FDA statement accepting KPV as one. [26]

Two healing blends, Coremend and one Deadpool pen, also contain BPC-157 and KPV alongside a larger TB-500 dose; they are covered in the healing and recovery stack. [27], [28] Vials pairing KPV with thymosin alpha-1 are covered in the immune stack.

KLOW

GHK-Cu with BPC-157, TB-500 and KPV. Most sellers list GHK-Cu 50 mg and 10 mg of each other part (80 mg). Because it is dosed by GHK-Cu, it is a weak source of KPV. [5], [21]

• KPV share: one-eighth of the 80 mg vial. A dose with 1 mg of GHK-Cu carries 200 mcg of KPV, the bottom of the injected KPV range, and 500 mcg of KPV takes 4 mg of powder. [21], [29]
• Where sellers disagree: one EU seller's 60 mg Klow has no KPV at all, and one protocol site calls the 80 mg formula the "Deadpool Stack". [22], [30]
• What GHK-Cu is claimed to add: skin and collagen repair. Almost all of its human studies used creams, gels or serums; none tested subcutaneous injection, and none is about the gut. [31]
• Stated amounts and regulators: one protocol page steps from about 2 to 6 mg of blend a day (1.25 to 3.75 mg of GHK-Cu), which carries 250 to 750 mcg of KPV. Health Canada named KLOW 80 mg in a 2025 seizure notice, the only regulator notice we found that names a blend with KPV. [32], [5]
• In community education groups: some people add a separate KPV dose to KLOW because it carries so little.
• Related stacks: healing and recovery and skin and hair.

Tri-Blend and Wolverine Plus

BPC-157, TB-500 and KPV at 10 mg each, so 1 mg of powder holds about 333 mcg of each. It is the most widely sold injectable vial that contains both gut peptides, plus TB-500.

• Where sellers disagree: the third part. Related Wolverine names can hold MGF (one catalog, under the plain Wolverine name) or Cartalax (sold as Wolverine 2.0), and one clinic menu describes its GLOW blend (BPC-157, thymosin beta-4, GHK-Cu, no KPV) as a "tri-blend". One seller sells the KPV version as "Tri-Blend (Phoenix)"; other sellers use Phoenix for tesamorelin with ipamorelin, a growth-hormone blend. [19], [20], [17], [15], [34]
• What TB-500 is claimed to add: whole-body repair by helping cells move into damaged tissue. Its guide finds no human studies of TB-500 itself, and none of its research is about the gut. [35] Full thymosin beta-4, which some TB-500 vials contain, reduced colitis in one 2026 mouse study; swallowed TB-500 has no data in any species, and lab work shows enzymes break it down. [36], [37]
• Stated amounts and regulators: one telehealth page sells a "compounded" liquid and gives 0.6 mg of each part once daily, Monday to Friday, for 4–12 weeks; we found no published schedule for the 10 mg powder vial. No regulator notice we found names Tri-Blend or Wolverine Plus. [33] A "compounded" label is not FDA approval: BPC-157 and KPV are not on the list of ingredients US pharmacies may compound from, and the July 2026 advisory vote has not changed that. [7], [8], [38]
• Testing: a seller-hosted certificate for one Wolverine Plus lot measured about 10–11 mg of each part; another BPC-157/TB-500/KPV vial measured 12–14 mg of each. One lot says nothing about other batches. [39], [40]
• Related stacks: the healing and recovery stack, where TB-500 and the other Wolverine blends are covered, and the tesamorelin and ipamorelin stack for the other Phoenix.

Why do people combine BPC-157 and KPV?

People combine them hoping BPC-157 repairs the gut lining while KPV calms inflammation. That is a rationale built on separate animal and cell studies, not proof. [9], [10]

• Two roles. Protocol pages describe BPC-157 as the repair peptide and KPV as the anti-inflammatory one, swallowed for a "local" gut effect or injected for a whole-body one. [9], [10], [13]
• Marketing. FDA's KPV review found it promoted for colitis and Crohn's disease, and the BPC-157 compounding nomination proposed capsules for ulcerative colitis, Crohn's disease and celiac disease. [8], [7]
• Social media. A 2026 study of popular Crohn's disease videos on Instagram listed a video promoting BPC-157, KPV and larazotide for bowel disease and celiac disease among the videos it rated harmful, noting none is FDA-approved. [41]
• Convenience. One capsule or one vial replaces two products. [1], [2]

In community education groups, people use the pair for reflux, bloating, IBS, gut trouble after antibiotics or on GLP-1 weight-loss drugs, and bowel disease, usually alongside other treatments.

What does the evidence show?

No study has tested BPC-157 with KPV, and neither peptide has been shown to help a gut condition in people.

BPC-157

The only gut trial in people used a BPC-157 enema in ulcerative colitis. FDA's review says 53 people were randomized and 46 finished, the results appeared only as a meeting abstract, and it did not establish a clear benefit. There are no human data for capsules or injections in gut disease. Its other human data are three small uncontrolled reports on the knee, bladder and IV safety. [7], [42] Full BPC-157 evidence

KPV

No human studies by any route and no registered trials. [8], [43] In mice with chemically caused colitis, KPV dissolved in drinking water reduced inflammation, and gut-lining cells take it in through a transporter called PepT1. [44], [45] But in a 2026 mouse study, plain KPV given by mouth at 1 mg/kg a day showed no benefit, while a chemically protected version worked. Much newer gut research uses nanoparticles or protected forms, not the plain peptide sold in capsules. [46], [47] The only human bowel-disease trial of a related peptide used KdPT, a different molecule. [48] Full KPV evidence

The combination

• No studies. Searches of PubMed, Europe PMC and ClinicalTrials.gov found no study, case report or registered trial of BPC-157 given with KPV, and none adding larazotide or zinc carnosine. [6]
• No oral data in people. Neither peptide's absorption from a capsule has been measured in people. BPC-157's has been measured only after injection into muscle in rats and dogs, and plain KPV by mouth showed no benefit in a 2026 mouse colitis study. [49], [8], [46]
• One public warning sign. A public forum post describes gut symptoms getting worse on a combined capsule. [50]

How do the gut stack protocols line up?

These are each part's most common injected protocol from its own guide. They are not a stack protocol: no source tested them together.

Capsules are the main gut form, so the oral rows from each guide are shown separately. There is no measured conversion between oral and injected amounts for either peptide.

Schedules published for the combination

Each row is a complete schedule from one page, with that page's amounts kept together. Oral and injected schedules are in separate tables.

The mixed-vial page's own worked example (5 mg + 5 mg with 2 mL) puts about 250 mcg of each in 0.1 mL. [14]

What one milligram of each blend contains

Arithmetic from each vial's listed amounts, not a dose.

How people line them up

Most sources take both at the same time each day, as one capsule or one injection. Oral schedules often say an empty stomach, while one page says KPV can be taken with or without food; no study has tested timing. [9], [13], [10] In community education groups, routes split opinion: some say injections did nothing for their gut while capsules helped, others the reverse, and some combine morning capsules with evening injections.

These schedules come from protocol sources for each part; no trial has tested this combination.

Plan it once. Two peptides, two routes or a stepped course are easy to mix up.

What are the overlapping risks and interactions?

Neither part has been safety-tested in people for gut use, and the pair has never been tested. The biggest practical risk is dropping prescribed treatment for an unproven stack; the others are unknown effects, untraceable reactions and products that do not match the label. [7], [8]

• Do not stop prescribed treatment. That includes biologics, other bowel-disease medicines, acid-reflux drugs and antibiotics. No study has tested either peptide instead of, or alongside, any of them. In public accounts from people with Crohn's disease or ulcerative colitis who felt better, they were also on prescribed medicines. [8], [55], [56]
• Gut symptoms need a diagnosis. "Gut healing" covers reflux, IBS, bowel disease and more. Bleeding, weight loss, trouble swallowing, persistent vomiting or anaemia need a doctor, not a peptide.
• Few safety studies. FDA found no standard toxicity, reproductive or cancer studies for either peptide, and raised immune reactions as a concern for injected peptides. [7], [8]
• Reactions cannot be traced. With two or more peptides, plus capsule extras, a side effect cannot be pinned on one part; FDA said the same about a two-peptide BPC-157 product. [7] In community education groups, reported problems include loose stools, capsule stomach upset and reflux flares.
• Blood vessels and tumours (theoretical). BPC-157 promotes blood-vessel growth in animals. In mice, oral KPV prevented bowel tumours linked to colitis but not inherited ones, which says nothing about people. [7], [45]
• Wrong or missing contents. A vial sold as BPC-157 contained none in one independent test, and in a 2026 preprint (not peer reviewed) of consumer-submitted tests, TB-500 (in Tri-Blend, Wolverine Plus and KLOW) had the highest share of samples missing the stated peptide, about 1 in 10. [57], [58]

Interactions. No interaction between BPC-157 and KPV, or with any medicine, has been studied; that is an absence of data, not evidence of safety. In community education groups, the stack is often taken alongside reflux medicines, GLP-1 weight-loss drugs, antibiotics or biologics.

Be especially cautious or avoid them in pregnancy, breastfeeding or when trying to conceive; under 18; with a current or past cancer; on immune-suppressing or biologic treatment; with diagnosed bowel disease; and in competitive sport.

Legal and sport status (checked September 2026):

• United States: neither part is FDA-approved. FDA staff recommended against allowing BPC-157 and KPV in pharmacy compounding; an advisory committee voted 8 to 6, with 1 abstention, in favour of each in July 2026, but no final rule has followed. [7], [8], [59], [60], [38] The Department of Defense supplement-safety program says BPC-157 is not a dietary ingredient. [26]
• Canada: Health Canada's April 2026 advisory lists BPC-157 and KPV among seized unauthorized injectable peptides, and a 2025 seizure notice named KLOW. [61], [5]
• Australia: BPC-157 has been prescription-only (Schedule 4) since June 2024, and TB-500 is Schedule 4 in the June 2026 Poisons Standard. KPV is not listed, which is not approval. [62], [63]
• Sport: WADA 2026 names BPC-157 as a non-approved substance and TB-500 as a prohibited growth factor, so Tri-Blend, Wolverine Plus and KLOW are banned. KPV is not named, but S0 bans all non-approved substances, so athletes should treat it as banned. [64]

What should be monitored?

No official monitoring guidance exists. What studies of the parts measured, and what matters for gut use:

• Digestive health: reflux, stool frequency and form, bloating and abdominal pain, logged before starting so there is a baseline.
• Inflammation: CRP, and for diagnosed bowel disease the tests your doctor already uses; the colitis trial used a disease-activity score. [7]
• Blood work: kidney and liver markers and blood counts, checked in the BPC-157 IV safety study. [65]
• Side effects: injection-site lumps or pain, rashes, stomach upset and changes in energy, sleep or mood.

On a blend or multi-ingredient capsule, the only way to find the cause of a reaction is to stop and talk to a clinician before restarting anything.

What happens when you stop?

Stopping has not been studied for either part, and nobody has studied stopping one while continuing the other. [7], [8]

In community education groups, some describe reflux or bloating returning within days of running out, others lasting relief; most were changing diet, weight or medicines at the same time. One describes capsule stomach upset settling within two days of stopping.

Premixed blend or separate products?

A capsule or premixed vial is simpler, but it fixes the ratio, hides which part caused a side effect, and has never been tested for stability with its parts mixed. Separate products take more steps but keep each amount adjustable and traceable.

• Mixing and stability. No published study shows whether BPC-157 and KPV stay stable together in one vial, syringe or capsule, and even BPC-157 alone has no published stability testing. Capsule shelf-life claims are seller statements. [66], [67]
• The ratio is locked. In a 1:1:1 Tri-Blend, raising KPV from 500 mcg to 1 mg also doubles BPC-157 and TB-500. In KLOW, 500 mcg of KPV comes with 2.5 mg of GHK-Cu. If one part upsets you, you cannot lower it alone. [3], [5]
• Tracking and troubleshooting. With separate products, a reaction can be narrowed to one part; with a blend or multi-ingredient capsule, it cannot. [7]
• Routes are separate exposures. A capsule amount and an injected amount are not interchangeable, so switching routes is starting a new, untested schedule. [53], [54]
• Units. Blend doses are weights of the whole powder: "1.5 mg of Tri-Blend" is 500 mcg of each part, and capsule labels mix mcg and mg. Work out syringe units for your own vial with the reconstitution calculator.

Common questions about the gut peptide stack

Do BPC-157 and KPV capsules work for gut problems?

Nobody has shown that they do. No study has tested the capsules, or the pair by any route, in people or animals. BPC-157's only gut trial used an enema and found no clear benefit, KPV has no human data, and plain KPV by mouth did nothing in a 2026 mouse colitis study. [6], [7], [8], [46]

Is Tri-Blend the same as Wolverine Plus?

Usually, yes. Both are most often BPC-157, TB-500 and KPV at 10 mg each. But related Wolverine names can hold MGF or Cartalax instead, and one clinic menu describes a GLOW blend without KPV as a "tri-blend", so check the label. [3], [4], [19], [20], [17]

Is KLOW good for the gut?

It is a weak source of KPV. KLOW is dosed by its GHK-Cu, so a dose from the usual 80 mg vial carries one-fifth as much KPV as GHK-Cu, and some vials sold as Klow have no KPV. No KLOW study exists for any use. [5], [21], [22]

Can I stop my reflux or IBD medicine if the stack helps?

No, not without your doctor. Neither peptide has been tested instead of any prescribed treatment, and feeling better while on both does not show which one helped. [8]

Related guides

How this guide was researched

How this guide was made

This stack guide was built from the verified sources of the BPC-157 and KPV guides and the healing and recovery stack, re-citing the original documents rather than those guides. New research covered only what the combination raises: studies of the pair, capsule and blend contents, naming, and regulator notices. Community education groups informed the descriptions of how people use the stack; no private post is quoted or linked.

The research file holds 97 records, 89 verified against the original page or document; this guide cites 67. Seller pages are cited only for listed contents, never as evidence of purity or effect.

Drafting used AI assistance under Doserly's editorial rules, followed by source checks and editorial review. It is general education, not medical advice.

Explore the sources